Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 44Lymphoma, Mantle-Cell 22Lymphoma, Non-Hodgkin 15Lymphoma, Large B-Cell, Diffuse 13Lymphoma, Follicular 10Waldenstrom Macroglobulinemia 9Lymphoma 9Lymphoma, B-Cell, Marginal Zone 7Leukemia 7Recurrence 6Neoplasms 6Lymphoma, B-Cell 5Leukemia, B-Cell 5Bronchiolitis Obliterans Syndrome 5Multiple Myeloma 3Leukemia, Lymphoid 3Hematologic Diseases 3Graft vs Host Disease 3Burkitt Lymphoma 3Melanoma 2Leukemia, Prolymphocytic 2Leukemia, Hairy Cell 2Hematologic Neoplasms 2Glioblastoma 2Brain Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms, Castration-Resistant 1Primary Central Nervous System Lymphoma (PCNSL) 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurologic Manifestations 1

Interventions

Cyclophosphamide 6Vincristine 3Temozolomide 3Radiotherapy 3Cisplatin 3Automobiles 3fludarabine 2Etoposide 2Eflornithine 2Carboplatin 2omburtamab I-131 1ibrutinib 1gallium Ga 68 dotatate 1etoposide phosphate 1belzutifan 1Zoledronic Acid 1Thiotepa 1Tamoxifen 1Standard of Care 1Radiotherapy, Image-Guided 1Pemetrexed 1ONC206 1Nivolumab 1Mesna 1Maintenance Chemotherapy 1Lomustine 1Isotretinoin 1Induction Chemotherapy 1Hydrocortisone 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × ibrutinib × 1 year × Clear all
NCT05106296 2026-01-09

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Augusta University

Phase 1 Recruiting
37 enrolled
CNS

Brain Neoplasms, Ependymoma, Glioblastoma, Medulloblastoma, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡